{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:18:58Z","timestamp":1783153138089,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004271","name":"University of Rome La Sapienza","doi-asserted-by":"publisher","award":["RM1241910A49FC94"],"award-info":[{"award-number":["RM1241910A49FC94"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"University of Rome La Sapienza","doi-asserted-by":"publisher","award":["RG123188B49A8CB3"],"award-info":[{"award-number":["RG123188B49A8CB3"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rmed.2026.108930","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:56:11Z","timestamp":1780556171000},"page":"108930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term therapy with elexacaftor\/tezacaftor\/ivacaftor improves cystic fibrosis lung disease and monocyte function"],"prefix":"10.1016","volume":"260","author":[{"given":"Gloria","family":"Sangiorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-0287","authenticated-orcid":false,"given":"Luca","family":"Cavinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cristoferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9753-9477","authenticated-orcid":false,"given":"Valentina","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorentina","family":"Ascenzioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108930_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2026.108930_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108930_bib3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2026.108930_bib4","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2026.108930_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108930_bib6","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2026.108930_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108930_bib8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3 open-label extension study","volume":"211","author":"Daines","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108930_bib9","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children \u22656 years with cystic fibrosis and at least one F508del allele: a 192-Week, phase 3, open-label extension study","volume":"211","author":"Wainwright","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108930_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108930_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.108930_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108930_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304555","article-title":"Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del","volume":"19","author":"Jarosz-Griffiths","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2026.108930_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/thorax-2024-222242","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on systemic inflammation in cystic fibrosis","volume":"80","author":"Maher","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108930_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2025","article-title":"Reduction of systemic inflammation by elexacaftor\/tezacaftor\/ivacaftor correlates with lung function improvement in cystic fibrosis","author":"Halle","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108930_bib16","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","author":"Sagel","year":"2025","journal-title":"Annals ATS"},{"key":"10.1016\/j.rmed.2026.108930_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/Tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.rmed.2026.108930_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00725-2022","article-title":"Elexacaftor\/Tezacaftor\/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis","volume":"61","author":"Cavinato","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108930_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108930_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108930_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38300-9","article-title":"Comparative effects of CFTR modulators on phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages","volume":"13","author":"Aridgides","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.rmed.2026.108930_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum induction trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108930_bib23","doi-asserted-by":"crossref","first-page":"L719","DOI":"10.1152\/ajplung.00431.2015","article-title":"Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications","volume":"311","author":"McClure","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.rmed.2026.108930_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70083","article-title":"Improved clinical outcomes with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease: real-world evidence from an Italian single\u2010center study","volume":"13","author":"Perrotta","year":"2025","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.rmed.2026.108930_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.rmed.2026.108930_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-Modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.rmed.2026.108930_bib27","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3390\/ijms22105262","article-title":"Partial rescue of F508del-CFTR stability and trafficking defects by double corrector treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.rmed.2026.108930_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108930_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1114584","article-title":"Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy","volume":"14","author":"Stanke","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2026.108930_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108930_bib31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jcf.2023.04.012","article-title":"The combination elexacaftor\/tezacaftor\/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner","volume":"22","author":"Liessi","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108930_bib32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:48:15Z","timestamp":1783151295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S0954611126002982"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108930","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term therapy with elexacaftor\/tezacaftor\/ivacaftor improves cystic fibrosis lung disease and monocyte function","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108930"}}